Predictors of pharmacotherapy response in anxiety disorders

被引：15
作者：
Denys D. [1 ]
de Geus F. [1 ]
机构：
[1] Rudolf Magnus Institute of Neuroscience, Department of Psychiatry, University Medical Center, 3508 GA Utrecht
来源：
Current Psychiatry Reports | 2005年 / 7卷 / 4期
关键词：
Single Photon Emission Compute Tomography; Heart Rate Variability; Anxiety Disorder; Paroxetine; Social Phobia;
D O I：
10.1007/s11920-005-0078-4
中图分类号：
学科分类号：
摘要：
Although treatment with different compounds such as tricyclic antidepressants, selective serotonin reuptake inhibitors, high-potency benzodiazepines, and monoamine oxidase inhibitors has been proven effective in anxiety disorders, 20% to 40% of patients are nonresponders. Given the limited efficacy, the delayed onset of response (it takes several weeks before a clinical effect can be seen for most of these drugs), and the occurrence of side effects associated with pharmacotherapy, predicting response in anxiety disorders would be immensely valuable. This review surveys the literature over the past years on predictors of response to pharmacotherapy in obsessive-compulsive disorder, social anxiety disorder, panic disorder, and posttraumatic stress disorder. Prediction of treatment response may be founded on demographic and clinical variables, neurochemical and electrophysiologic parameters, imaging studies, and genetic markers. Copyright © 2005 by Current Science Inc.
引用
收藏
页码：252 / 257
页数：5
相关论文
共 63 条
[1]  
Fineberg N.A., Gale T.M., Evidence-based pharmacotherapy of obsessive-compulsive disorder, Int. J. Neuropsychopharmacol., 8, pp. 107-129, (2005)
[2]  
Goodman W.K., Price L.H., Rasmussen S.A., Et al., The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability, Arch. Gen. Psychiatry, 46, pp. 1006-1011, (1989)
[3]  
Goodman W.K., Price L.H., Rasmussen S.A., Et al., The Yale-Brown Obsessive Compulsive Scale. II. Validity, Arch. Gen. Psychiatry, 46, pp. 1012-1016, (1989)
[4]  
Denys D., Burger H., van Megen H., Et al., A score for predicting response to pharmacotherapy in obsessive-compulsive disorder, Int. Clin. Psychopharmacol., 18, pp. 315-322, (2003)
[5]  
Mataix-Cols D., Rosario-Campos M.C., Leckman J.F., A multi-dimensional model of obsessive-compulsive disorder, Am. J. Psychiatry, 162, pp. 228-238, (2005)
[6]  
Mataix-Cols D., Rauch S.L., Manzo P.A., Et al., The use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder, Am. J. Psychiatry, 156, pp. 1409-1416, (1999)
[7]  
Neziroglu F., Pinto A., Yaryura-Tobias J.A., Et al., Overvalued ideation as a predictor of fluvoxamine response in patients with obsessive-compulsive disorder, Psychiatry Res., 125, pp. 53-60, (2004)
[8]  
Ravi K., Ravi V., Samar B., Janardhan Reddy Y.C., Et al., Clinical characteristics and treatment response in poor and good insight obsessive-compulsive disorder, Eur. Psychiatry, 19, pp. 202-208, (2004)
[9]  
Delorme R., Chabane N., Callebert J., Et al., Platelet serotonergic predictors of clinical improvement in obsessive compulsive disorder, J. Clin. Psychopharmacol., 24, pp. 18-23, (2004)
[10]  
Bareggi S.R., Bianchi L., Cavallaro R., Et al., Citalopram concentrations and response in obsessive-compulsive disorder. Preliminary results, CNS Drugs, 18, pp. 329-335, (2004)
1234567